SCHEMBL17722654

SCHEMBL17722654

CCCCOC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](OCCCC)[C@@H]1OCCCC

nearest known ligand 0.47

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS2 O15393 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10142084 1.00 TMPRSS2 (0.34) TMPRSS2
SCHEMBL10142104 0.91 — —
SCHEMBL17722725 0.91 — —
SCHEMBL807680 0.91 TMPRSS2 (0.34) TMPRSS2
SCHEMBL16479532 0.91 TMPRSS2 (0.34) TMPRSS2
SCHEMBL17722655 0.88 — —
SCHEMBL15607071 0.86 — —
SCHEMBL18666888 0.86 TMPRSS2 (0.35) TMPRSS2
SCHEMBL10142123 0.86 — —
SCHEMBL10142421 0.86 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295214-A1 METHODS OF PREPARING 1`-CYANO NUCLEOSIDES GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
US-20230219993-A1 ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG VIGONVITA LIFE SCIENCES CO., LTD. (CN) 2023-07-13 — — US disclosed
US-9724360-B2 Methods for treating Filoviridae virus infections GILEAD SCIENCES, INC. (US) 2017-08-08 — — US disclosed
US-20160361330-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2016-12-15 — — US disclosed
US-20160122356-A1 METHODS FOR THE PREPARATION OF RIBOSIDES GILEAD SCIENCES, INC. 2016-05-05 — — US disclosed
US-20160122374-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2016-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122356-A1 METHODS FOR THE PREPARATION OF RIBOSIDES PRPS1, PRPF4, PRPF31 TMPRSS2 3100/4885
US-20160361330-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS PNP, PRPF4, RPIA TMPRSS2 1951/4885
US-20230295214-A1 METHODS OF PREPARING 1`-CYANO NUCLEOSIDES PNP, TYMP, DUT TMPRSS2 4737/4885
US-20230219993-A1 ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG PNP, TYMP, PIGS TMPRSS2 145/4885
US-20160122374-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS PNP, PRPF4, RPIA TMPRSS2 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback